trending Market Intelligence /marketintelligence/en/news-insights/trending/nLoxpKzMWtEAE0L3_WCzVA2 content esgSubNav
In This List

SkinBioTherapeutics starts trading on AIM

Case Study

Identifying PPE Suppliers During the Pandemic


Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

SkinBioTherapeutics starts trading on AIM

SkinBioTherapeutics plc's ordinary shares started trading on the London Stock Exchange's AIM market on April 5 under the ticker SBTX.

The company's IPO raised £4.5 million in gross proceeds with the issuance of 118,708,494 ordinary shares at 9 pence per share, including a cornerstone investment from U.K. equity investor Seneca Partners Ltd.

Estimated net proceeds from the offering were £4.1 million.

Cairn Financial Advisers LLP was the nominated adviser for the IPO and Turner Pope Investments Ltd. acted as the broker.

OptiBiotix Health PLC holds a significant stake in SkinBioTherapeutics.